Clinical Social Workers in W Springfield, MA Accepting Medicare
5 Clinical Social Workers found. Showing 1 - 5
 Niels W Cudnohufsky, LICSW, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2112 Riverdale St, W Springfield, MA 01089 Phone: 413-788-7366 Fax: 413-827-4269 |
 Ms. Kathleen L Varner, MSW LICSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 51 Park Ave, Suite 4, W Springfield, MA 01089 Phone: 413-781-2348 Fax: 413-785-5286 |
Ms. Jane H Katz, LICSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 2112 Riverdale St, W Springfield, MA 01089 Phone: 413-788-7366 Fax: 413-827-4204 |
Barry Rothenberg, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 10 Central St, Suite 27, W Springfield, MA 01089 Phone: 413-739-0712 |
Mary Kate Marple, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 201 Park Ave, W Springfield, MA 01089 Phone: 413-781-3307 Fax: 413-781-3315 |
News Archive
Sverica International acquires Center for Wound Healing
The Center for Wound Healing, Inc., a leading manager of comprehensive wound care treatment centers that offer wound care and hyperbaric oxygen therapy, today announced the completion of the acquisition of CFWH by Sverica International, a leading private equity firm, for approximately $41 million.
Study: Traffic-related air pollutants appear to thwart benefits of walking among older adults
Even short-term (2 hour) exposure to tiny particles of soot or dust found in traffic fumes on busy roads appears to thwart the benefits of walking on the heart and lungs among older adults (aged 60 or over), according to a study comparing the health effects of walking along a traffic-polluted road versus walking through a park.
High cholesterol may lead to high blood pressure in men
Men with high total cholesterol are much more likely to develop high blood pressure than men with low total cholesterol, according to a study in Hypertension: Journal of the American Heart Association.
FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) filed by Mallinckrodt Inc., a subsidiary of Covidien plc, for the 32 mg dose strength of EXALGO (hydromorphone HCl) Extended-Release Tablets (CII), for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.
› Verified 4 days ago